Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.

The term interstitial cystitis/bladder pain syndrome (IC/BPS) describes a heterogeneous lower urinary tract disorder that is challenging to diagnose and notoriously difficult to manage effectively.

"From a revenue, profit and loss perspective, actually, in many instances, they anticipate that physicians may actually make more money using the second-generation CVAC device compared to traditional ...

"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP. In this ...

According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.” The combination of benmelstobart (TQB2450) and anlotinib ...

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with ...

“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says ...

According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS. Certain phenotypic and genomic biomarkers were found to be prognostic for radiographic progression-free survival ...

The TiNivo-2 trial demonstrated that rechallenging ICI therapy does not improve outcomes in patients with renal cell carcinoma. In this interview, Toni K. Choueiri, MD, shares the background and key ...

Andrea Necchi, MD, reported that pCR was 42% (95% CI, 28-56) in cohort 1 and 23% (95% CI, 10-41) in cohort 2. Neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) with TAR-200 plus ...